| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dichloroacetate (DCA) is a metabolic modulator that targets the altered metabolic state of cancer cells by inhibiting PDKs. This action impacts several key pathways: • Reversal of the Warburg effect • Restoration of mitochondrial function and promotion of apoptosis • suppresses glycolysis and promotes oxidative phosphorylation, thereby increasing mitochondrial ROS-mediated apoptosis in tumor cells • Increase in ROS production leading to oxidative stress • Inhibition of cell cycle progression • Modulation of HIF-1α signaling: DCA might decrease HIF-1α stabilization, thereby reducing the expression of genes that support glycolysis, angiogenesis, and survival under low-oxygen conditions. -DCA has been primarily used in treating congenital lactic acidosis—a rare genetic disorder characterized by the buildup of lactic acid in the body. -DCA is an experimental anti-diabetic and lipid-lowering drug, as well as treating myocardial and cerebrovascular ischemia. -Do not add DCA to hot or warm beverages(theorical). DCA is unstable at higher temperatures -Caffeinated may increase effectiveness -Vitamin B1 reduces neuropathy (500mg-2500mg/day) -Possibly 20 grams of citric acid 20 minutes before taking DCA -Procaine, Diclofenac or Sulindac may increase SMCT1 -Omeprazole 80mg/day to increase DCA effectiveness -Scorpion venom to increase DCA effectiveness -Metformin 1000mg to 1500mg/day -Propranolol (Ref.) -Fenbendazole shows strong synergy when combined to DCA, So it may make very much sense to combine the two. "Note: DCA is not tumor cell specific,> and therefore the same shift in glucose metabolism that occurs in cancer cells will also take place in immune cells, leading to induction of Tregs (Ref.). In order to avoid this possibility, while using DCA I would also use Treg inhibitors such as Cimetidine (Ref.) or low dose Cyclophosphamide (Ref.)." "DCA should not be used in association with allopurinol, NSAIDs, or flavonoids because they reduce cellular DCA uptake." "triple association of DCA, metformin and celecoxib, which has never been experimentally tested in patients, deserves well planned phase II clinical trials" Research Dose: 10mg/kg/day and increase slowly to about 25mg/kg/day:(1/2morn,1/2evening) take 5 days on, 2 off? OR 2wks on/ 1wk off: https://www.thedcasite.com/dca_dosage.html Done by mixing it in water and drinking, suggested that DCA not be taken on an empty stomach. **** DCA-induced apoptosis in cancer cells requires sodium-coupled monocarboxylates transporter SLC5A8 (SMCT1) -Inhibitors of DNA methylation induce reactivation of SLC5A8 -Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. -SMCT1 was found to be stimulated by some other NSAIDs (diclofenac, meclofenamate and sulindac), by activin A143 and by the probiotic Lactobacillus plantarum. SMCT1 has been found to be inhibited by some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and indomethacin94), phytochemicals (resveratrol and quercetin) **** Hence these should be avoided with DCA(theorical). (also theorically AVOID Bromide, iodide and sulfite ) **** GSTZ1 an/or chloride anion transport inhibitors also reduce resistance to DCA (if the tumor expresses GSTZ1 and contains a high chloride anions level, the GSTZ1 will be stable, maintaining the resistance to DCA). -Dichloroacetate-dca-treatment-strategy GSTZ1 an/or chloride anion transport inhibitors. . -Etacrynic acid is a Cl(-)-ATPase inhibitor -Lansoprazole and Omeprazole inhibit chloride channels. -Chlorotoxin found in scorpion venom (see my post on scorpion venom) can also inhibit chlorine channels Sources: https://northernhealthproducts.com/shop/ https://www.dcalab.com/ Excellent DCA review Dichloroacetate — Dichloroacetate, usually administered as sodium dichloroacetate, is a small-molecule metabolic modulator that inhibits pyruvate dehydrogenase kinases and thereby activates the mitochondrial pyruvate dehydrogenase complex. It is formally classified as an investigational metabolic drug and pyruvate dehydrogenase kinase inhibitor. DCA is a synthetic chlorinated acetate historically investigated for congenital mitochondrial and lactic-acidosis disorders; it is not an approved anticancer therapy. Its principal translational limitation is the narrow separation between concentrations that alter tumor metabolism and chronic exposures associated with peripheral neuropathy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral DCA is systemically bioavailable, but its pharmacokinetics are nonlinear and time-dependent. DCA is metabolized primarily by GSTZ1, while DCA also irreversibly inhibits GSTZ1, producing reduced clearance and progressive drug accumulation during repeated exposure. GSTZ1 genotype, age and treatment duration can substantially alter plasma exposure. Chronic exposure is limited principally by reversible or incompletely reversible peripheral sensory and motor neuropathy; gastrointestinal, hepatic and hematologic adverse effects have also been reported. In-vitro vs systemic exposure relevance: Many anticancer studies use approximately 1–20 mM DCA, frequently 5–20 mM. Sustained human plasma concentrations at the upper end of this range are generally not achievable without substantial toxicity. Clinical PK data indicate that tolerated concentrations may inhibit constitutive PDK2 but may be inadequate for less-sensitive or highly induced PDK isoforms. Consequently, strong cytotoxicity observed at high millimolar concentrations should not be assumed to translate directly to patients. Clinical evidence status: Extensive preclinical evidence; several small phase I and phase II human studies; one randomized placebo-controlled phase II adjunct study with cisplatin chemoradiotherapy; no phase III validation and no regulatory approval for cancer. Early trials demonstrate measurable metabolic effects and generally manageable short-term administration, but objective anticancer efficacy remains inconsistent and unproven. A randomized head-and-neck cancer study did not establish a clear survival advantage, while reporting increased low-grade fever and thrombocytopenia. DCA remains an investigational adjunct rather than a standard anticancer treatment. Dichloroacetate Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr Older Table:
|
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:288 Target#:324 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid